経口投与はGLP-1の分泌を強力に促進し,ネズミの血糖反応を低下させる

Akiho Irie¹, Tohru Hira^1,2

¹Laboratory of Nutritional Biochemistry, Graduate School of Agriculture, Hokkaido University, Sapporo, Japan.

Bioscience, biotechnology, and biochemistry

|September 3, 2025

まとめ

アミノ酸であるL-ライシンは,ネズミのグルカゴン型ペプチド-1 (GLP-1) の分泌を効果的に刺激する. カルシウムとL-ライシンを併用すると,血糖値の管理に役立つことが示されています.

科学分野:

内分泌学
胃腸内科
代謝に関する研究

背景:

グルカゴン型ペプチド-1 (GLP-1) は,血糖と食欲を調節する重要なホルモンです.
栄養素はGLP-1の分泌を刺激しますが,特定のアミノ酸の影響は十分に調査されていません.

研究の目的:

GLP-1の分泌に対する口服用l-ライシン (Lys) の急性効果を in vivoで調査する.
ライス誘発のGLP-1放出のメカニズムを探求する.

主な方法:

スプラグ・ダウリー・ラットに,口服用l-ライシンとl-アラニンを投与した.
カルシウム感受受体 (CaSR) 反抗剤の十二指管経口投与
L- リシンとカルシウムを併用した経口グルコース耐性試験

主要な成果:

経口投与したl- リジンは,ラットにおけるGLP- 1の血濃度を著しく上昇させた.
l- リジンは,既知の分泌剤に匹敵する強力なGLP- 1刺激能力を示した.
リス誘発のGLP-1分泌を弱め,受容体を関与させた.
L- リシンとカルシウムを併用すると,GLP- 1の分泌が増加し,血糖値のコントロールが改善された.

結論:

L-ライシンはGLP-1分泌の強力なインダクターである.
L- リジンとカルシウムの組み合わせは,GLP-1の放出を促進する有望な戦略です.
このアプローチは,血糖値の管理に翻訳的な可能性を秘めています.

キーワード:

リンジーンカルシウムカルシウムセンサー受容体 (CaSR)グルカゴンのようなペプチド-1

さらに関連する動画

11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.7K

04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K

関連する概念動画

01:24

Glucagon-like Receptor Agonists

416

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

416

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

255

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

255

01:06

Oral Hypoglycemic Agents: Glinides

256

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

256

01:23

Dipeptidyl Peptidase 4 Inhibitors

252

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

252

01:15

Hypoglycemia and Glucagon

334

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

334

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

288

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

288

関連する実験動画